Mycovia Pharmaceuticals to Participate in On-Demand Women’s Health Panel at BIO Digital 2020

CEO Patrick Jordan and biopharmaceutical executives to discuss prioritizing women’s health to the forefront at the global virtual gathering of biotech industry companies

Durham, N.C. – June 8, 2020 – Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced that Chief Executive Officer Patrick Jordan will join the panel session “Redefining BioPharma in a Female-Forward World” to discuss the importance of women’s health at BIO Digital. BIO Digital will be held virtually from June 8-12 due to the COVID-19 pandemic. Mycovia’s oteseconazole (VT-1161), an oral antifungal product candidate for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), is currently in Phase 3 clinical development. RVVC is a debilitating, chronic infectious condition that affects nearly 138 million women worldwide each year and for which there is currently no FDA-approved treatment in the U.S.